2024澳门原料网站-免费完整资料

Be the most trusted biotech company

2024-09-30

Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
2024-09-29

024 CSCO | 复宏汉霖H药汉斯状®研究数据发布
2024-09-21

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
2024-09-18

Latest Results of HANSIZHUANG and HANQUYOU Released at 2024 ESMO
2024-09-13

Meet Henlius at CPHI Worldwide 2024
2024-09-09

Latest Results of Serplulimab in the Field of SCLC Released at 2024 WCLC
2024-09-02

IND Application of Henlius’ Pembrolizumab Biosimilar Approved by NMPA
2024-08-26

Henlius Maintains Patient-Centric Focus, Drives Sustainable Growth, and Accelerates Overseas Expansion in 2024 H1
2024-08-22

Henlius Trastuzumab Receives Approval in Canada